Cid A R, Calabuig M, Cortina V, Casaña P, Haya S, Moret A, Cabrera N, Aznar J A
Congenital Coagulopathies Unit, La Fe University Hospital, Valencia, Spain.
Haemophilia. 2008 Sep;14(5):1049-54. doi: 10.1111/j.1365-2516.2008.01781.x. Epub 2008 Jun 5.
The discrepancy of the levels of factor VIII activity (FVIII:C) by different assays in some mild and moderate haemophilic A patients has been long known. Specific mutations affecting FVIII:C discrepancies have been described. No consensus exit as to which method most accurately represents the FVIII cofactor function in vivo and which has a better correlation with the haemorrhagic clinical expression. We studied 163 mild A haemophiliacs, and detected discrepancies in 20% of the patients, most of whom presented higher levels of FVIII:C with the one-stage assay. In nine families, the FVIII mutation was found, while three showed mutations not previously described (Leu1978Phe and Ser1791Pro associated with higher levels of FVIII:C by one-stage method; Arg1639His in a patient with low level of FVIII:C by the one-stage, but normal, chromogenic assay). Assessing the level of FVIII:C by different methods could help to learn the possible haemorrhagic expressions of patients.
长期以来,人们一直知道一些轻度和中度甲型血友病患者通过不同检测方法测得的凝血因子VIII活性(FVIII:C)水平存在差异。已经描述了影响FVIII:C差异的特定突变。对于哪种方法最准确地代表体内FVIII辅助因子功能以及哪种方法与出血临床表型具有更好的相关性,目前尚无共识。我们研究了163例轻度甲型血友病患者,发现20%的患者存在差异,其中大多数患者通过一期法测得的FVIII:C水平较高。在9个家族中发现了FVIII突变,而3个家族显示出先前未描述的突变(Leu1978Phe和Ser1791Pro与一期法测得的FVIII:C水平较高相关;Arg1639His出现在一名通过一期法测得FVIII:C水平较低但发色底物法检测正常的患者中)。通过不同方法评估FVIII:C水平有助于了解患者可能的出血表现。